Drug Profile


Alternative Names: hI-con1; hIcon1; ICON-1

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yale University
  • Developer Iconic Therapeutics; Yale University
  • Class Antineoplastics; Eye disorder therapies; Immunoconjugates; Immunoproteins; Recombinant fusion proteins
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Natural killer cell stimulants; Thromboplastin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Phase I Uveal melanoma
  • Research Solid tumours
  • No development reported Cancer

Most Recent Events

  • 22 Aug 2017 hI-con1 is available for licensing as of 22 Aug 2017. www.iconictherapeutics.com
  • 01 Sep 2016 Iconic Therapeutics completes the phase II EMERGE trial for Wet age-related macular degeneration (In adults, In the elderly) in USA (NCT02358889)
  • 09 Aug 2016 Early research in Solid tumours in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top